US88322Q1085 - TGTX - A1JXW7 (LSSI)
TG THERAPEUTICSCS Aktie
22,72 EUR
Aktuelle Kurse von TG THERAPEUTICSCS
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
TGTX
|
USD
|
20.09.2024 01:55
|
25,38 USD
| 25,25 USD | 0,51 % |
London |
0VGI.L
|
USD
|
19.09.2024 17:12
|
25,36 USD
| 25,25 USD | 0,45 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 5,21 % | 5,44 % | 44,26 % | 66,37 % | 156,09 % | 292,63 % |
Firmenprofil zu TG THERAPEUTICSCS Aktie
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Unternehmensdaten zur TG THERAPEUTICSCS Aktie
Name TG THERAPEUTICSCS
Firma TG Therapeutics, Inc.
Symbol TGTX
Website https://www.tgtherapeutics.com
Heimatbörse
Lang & Schwarz
WKN A1JXW7
ISIN US88322Q1085
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Michael S. Weiss Esq.
Marktkapitalisierung 3 Mrd.
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,3 T
Adresse 2 Gansevoort Street, 10014 New York
IPO Datum 2010-05-03
Aktien-Splits
Datum | Split |
---|---|
30.04.2012 | 100:5625 |
19.07.2011 | 1:1 |
14.07.2011 | 1:50 |
Aktien Kennungs-Wechsel
Datum | Von | Zu |
---|---|---|
27.04.2012 | MHAN | TGTX |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | NKB2.F |
London | 0VGI.L |
NASDAQ | TGTX |
Weitere Aktien
Investoren die TG THERAPEUTICSCS halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024